Oncology, inclusive of Medical and Radiation, is a branch of medicine which specialises in the diagnosis and treatment of cancer. What could not be treated well in the past is now being taken care of through different methods where technology is playing a transformative role. Technological innovations like CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), Artificial Intelligence, telehealth, cryo-electron microscopy, the Infinium Assay and robotic surgery are profoundly helpful in accelerating progress against cancer.
Preeti Tupsakhare, a leading figure in healthcare technology, has highlighted tech’s significance in healthcare in her publication, “Revolutionizing Oncology Solutions with AI on Low-Code Platforms.” Featured in the Journal of Oncology Research Review & Reports, this work delves into the transformative potential of integrating Artificial Intelligence (AI) and low-code development platforms in reshaping cancer care. Tupsakhare’s insights shed light on how these innovations can accelerate advancements in oncology, making sophisticated tools more accessible to healthcare providers. She also excels at software engineering for healthcare and her work, “Ensuring Scalability and Stability in Low-Code Platforms: Best Practices and Challenges” and “Improving Clinical Decision Support in Health Care Through AIs,” published in esteemed journals offer strategic insights into building robust applications while enhancing clinical decision-making.
Her efforts in the realm of low-code oncology tools are setting new benchmarks for personalized cancer treatment. She has streamlined critical processes such as preauthorization and diagnostics. The impact of this work is quantifiable as the development time has been reduced by 30%, and costs have dropped by 20%, demonstrating the efficacy of low-code solutions across the healthcare landscape. The creation of advanced tools for personalized treatment and predictive analytics led by her have led to an increase of 25% in treatment efficiency and a reduction of 12% in chemotherapy adjudication errors, ultimately resulting in improved patient outcomes.
A core tenet of her philosophy is democratizing healthcare through low-code platforms. “Traditional development models are often resource-intensive and exclusive,” she explains and adds, “With low-code, we’ve proven that scalable, powerful solutions can be built in a fraction of the time, while involving a broader range of healthcare professionals in the process.” This approach has transformed how non-technical staff can participate in system improvements, that would facilitate the adoption of new technologies and broaden the scope of involvement in healthcare innovation.
Addressing pressing challenges within oncology should be focused upon, particularly concerning the technical complexities surrounding AI development. The importance of real-time patient monitoring and predictive analytics should be emphasized. “By making these tools more accessible, we can ensure better, faster, and more equitable outcomes for patients,” Tupsakhare adds, highlighting her vision for a more inclusive healthcare system.
Looking ahead, industry leaders foresee the landscape of oncology care where AI and low-code platforms converge to provide personalized, efficient, and cost-effective treatments. A shift toward inclusive, technology-driven healthcare solutions that promise to redefine patientcare is the need of the hour. With appropriate technological advancements, healthcare can be improved worldwide.
